10-Q: Theriva Biologics Reports Q3 2024 Results, Provides Clinical Pipeline Update

Theriva Biologics reported its third quarter 2024 financial results and provided updates on its clinical development programs, including the completion of enrollment in a Phase 2 trial for pancreatic cancer.

Summary

• Theriva Biologics, a clinical-stage company, released its financial results for the third quarter of 2024, showing a net loss of $7.7 million, or $6.81 per share.
• The company's operating expenses totaled $7.9 million, including $2.3 million in general and administrative costs and $2.7 million in research and development expenses.
• A significant portion of the operating expenses was attributed to a $1.3 million impairment of in-process research and development and a $1.5 million goodwill impairment.
• The company's cash and cash equivalents stood at $16.4 million as of September 30, 2024, a decrease from $23.2 million at the end of 2023.
• Theriva Biologics completed a public offering in September 2024, raising approximately $2.5 million in gross proceeds.
• The company also completed enrollment in its Phase 2b VIRAGE clinical trial for VCN-01 in pancreatic cancer, with 92 patients enrolled.
• The company received Rare Pediatric Drug Designation from the FDA for VCN-01 for the treatment of retinoblastoma.
• The company is actively pursuing additional equity or debt financing to fund its operations and clinical trials.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline, the financial results are concerning, with a significant net loss, impairments, and a limited cash runway. The company's dependence on future capital raises and the going concern warning from auditors contribute to a negative sentiment.

Positives

• The company completed enrollment in the Phase 2b VIRAGE trial for VCN-01 in pancreatic cancer.
• The company received Rare Pediatric Drug Designation for VCN-01 for retinoblastoma from the FDA.
• The company successfully raised $2.5 million in gross proceeds through a public offering.
• The company's research and development expenses decreased by 32% compared to the same quarter last year.
• The company has been awarded funding of 2.28 million from the National Knowledge Transfer Program of the Spanish government to support a collaboration with the Universitat Autnoma de Barcelona.

Negatives

• The company reported a net loss of $7.7 million for the third quarter of 2024.
• The company experienced a $1.3 million impairment of in-process research and development and a $1.5 million goodwill impairment.
• The company's cash and cash equivalents decreased to $16.4 million as of September 30, 2024.
• The company has an accumulated deficit of $330.5 million as of September 30, 2024.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may need to delay, reduce, or eliminate certain development programs if funding is not secured.
• The company's stock price may be negatively impacted by the company's financial performance and the risk of delisting from the NYSE American.
• The company has identified material weaknesses in its internal controls, which could affect the accuracy of financial reporting.
• The company's future clinical trials will require significant financing or a significant partnership.

Future Outlook

The company anticipates research and development expenses to increase as it continues its VIRAGE Phase 2 clinical trial of VCN-01 and plans for its Phase 3 clinical trial of VCN-01 in PDAC, advances its VCN-01 program in retinoblastoma, expands GMP manufacturing activities for VCN-01, and continues supporting its other preclinical and discovery initiatives. The company believes its current cash will be sufficient to fund operations into the third quarter of 2025, but will need to raise additional capital to fund future clinical trials and operations beyond that point.

Management Comments

• Management believes its plan, which is focused on the advancement of VCN-01 will allow us to meet our financial obligations, further advance key products, and maintain our planned operations.
• Management believes the efforts taken to date and the planned remediation will improve the effectiveness of our internal control over financial reporting.

Industry Context

The company's focus on oncolytic virotherapy aligns with the growing interest in novel cancer treatments that leverage the immune system. The company's pipeline targets areas of high unmet need, such as pancreatic cancer and retinoblastoma, which are areas of significant research and development activity in the biotechnology industry.

Comparison to Industry Standards

• The company's net loss per share of $6.81 for the quarter is higher than many comparable biotech companies at a similar stage of development, reflecting the high costs of clinical trials and research.
• The company's cash burn rate of approximately $12.2 million for the nine months ended September 30, 2024, is typical for a clinical-stage biotech company, but the company's cash runway is limited.
• The completion of enrollment in the Phase 2b VIRAGE trial is a positive milestone, but the company's success will depend on the trial's results and the ability to secure funding for future trials.
• The receipt of Rare Pediatric Drug Designation for VCN-01 in retinoblastoma is a positive development, as it provides potential market exclusivity and a priority review voucher, which can be valuable assets.
• The company's reliance on external funding is a common risk for biotech companies, and the company's ability to secure additional capital will be critical for its future success.

Related Party Transactions

• The company paid compensation to Mary Ann Shallcross of $38,000 and $114,000 during the three and nine months ended September 30, 2024, respectively.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential delays or reductions in development programs if funding is not secured.
• Patients may benefit from the company's clinical development programs if they are successful.
• Creditors may be at risk if the company is unable to continue as a going concern.

Next Steps

• The company will continue to advance its VIRAGE Phase 2 clinical trial of VCN-01 in pancreatic cancer.
• The company will prepare for a potential Phase 3 clinical trial of VCN-01 in pancreatic cancer.
• The company will advance its VCN-01 program in retinoblastoma.
• The company will expand GMP manufacturing activities for VCN-01.
• The company will continue to support its other preclinical and discovery initiatives.
• The company will seek additional funding through equity or debt financing.
• The company will explore value creation options for its SYN-004 and SYN-020 assets, including out-licensing or partnering.

Key Dates

Keywords

Theriva Biologics, VCN-01, pancreatic cancer, retinoblastoma, clinical trial, oncolytic virus, SYN-004, SYN-020, financial results, biotechnology, orphan drug designation, rare pediatric disease designation